• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Silo Pharma Inc (NQ: SILO )

    1.320 +0.040 (+3.13%)
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 11, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Silo Pharma Inc

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis
    Via Investor Brand Network
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advances Clinical Study Examining Psilocybin’s Effect on Inflammation
    Via Investor Brand Network
    Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Reports Positive Results from SPU- 21 Arthritis Study
    Via Investor Brand Network
    Silo Pharma Stock Surges After Positive Study Results From Arthritis Study
    Via Benzinga
    Stocks That Hit 52-Week Lows On Friday
      During Friday's trading, 71 companies set new 52-week lows. 
    Via Benzinga
    What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
    What a year for psychedelics! 
    Via Benzinga
    Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Horizon Global Corporation (NYSE: HZN) shares surged 341% to $1.7161 after the company announced it will be acquired by First Brands Group. 
    Via Benzinga
    Why Tesla Shares Are Trading Lower; Here Are 32 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
    Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
    Via Benzinga
    Nasdaq Falls 100 Points; Dermata Therapeutics Shares Surge
    U.S. stocks traded lower midway through trading, with the Nasdaq Composite dropping around 100 points on Friday. 
    Via Benzinga
    Silo Pharma (NASDAQ: SILO) Reports Positive Results from Dose Optimization Study for SPU-21 and Treatment of Arthritis
    Silo Pharma, Inc. (NASDAQ: SILO) operates as a development-stage biopharmaceutical company, which is focused on combining traditional therapies with psychedelics 
    Via Spotlight Growth
    US Stocks Open Lower; Dow Drops 250 Points
    U.S. stocks traded lower this morning, with the Dow Jones dropping around 250 points on Friday. 
    Via Benzinga
    Global Rheumatoid Arthritis Drugs Market Expected To Hit US$ 70 Billion By 2030
    EQNX::TICKER_START (NASDAQ:SILO),(NASDAQ:BXRX),(NASDAQ:HOTH),(NASDAQ:KALA),(NASDAQ:NUWE) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Silo Pharma Announces Positive Study Results of SPU
    21 for Arthritis – SPU-21 effective in controlling arthritis progression SPU-21 Demonstrates Positive Data in Arthritis Suppression using Silo’s Novel Joint Homing Peptide Englewood Cliffs, – December... 
    Via FinancialNewsMedia
    Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis
    From Silo Pharma, Inc.
    Via GlobeNewswire
    InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) CEO Discusses Advancement of Pipeline, Positioning in Shareholder Letter
    Via Investor Brand Network
    Silo Pharma Issues Letter to Shareholders Detailing Progress on Pipeline Assets Combining Traditional Therapeutics with Psychedelic Medicine
    From Silo Pharma, Inc.
    Via GlobeNewswire
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Advancing Research of SPU-21 in Human Synovial Tissue
    Via Investor Brand Network
    Silo Pharma Initiates Study of Novel Joint Homing Peptide in Human Tissue
    From Silo Pharma, Inc.
    Via GlobeNewswire
    7 Millionaire-Maker Stocks You Will Regret Not Buying This Year
    With the market shifting toward a deflationary stance, investors should target these robust millionaire-maker stocks to buy. 
    Via InvestorPlace
    Novel Psychedelic Compound For The Treatment Of Fibromyalgia Begins Dosing In Safety Trial
    Developmental-stage psychedelics biotech company Silo Pharma Inc. (NASDAQ: SILO) has begu 
    Via Benzinga
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Milestone in IND-Enabling Study of Time-Released Ketamine Formulation
    Via Investor Brand Network
    Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation
    From Silo Pharma, Inc.
    Via GlobeNewswire
    New Psychedelic Journal to Focus on Publishing Psychedelic Research
    Via Investor Brand Network
    Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease
    Via Investor Brand Network
    PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Confident in Preclinical Work on Its Novel Ketamine Formulation
    Via Investor Brand Network
    Microscopy Provides Insights on Psychedelics Action Inside Neuropathways
    Via Investor Brand Network
    PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector
    Via Investor Brand Network
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.